Avecho meets TGA ahead of Phase III Clinical Trial
Filed with ASX · · 2 pages · English
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- AVE receives final ethics approval for Phase III CBD trial
- Appendix 4E and Annual Report 31 December 2023
- December 2023 Quarterly Activities Report & Appendix 4C
- September 2023 Quarterly Activities Report & Appendix 4C
- Reinstatement to Official Quotation
Later from Avecho Biotechnology
- Avecho commences Phase III insomnia trial
- March 2024 Quarterly Activities Report & Appendix 4C
- First Patient dosed in Phase III insomnia trial
- Chair's Address and CEO Presentation
- June 2024 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology